Search

Your search keyword '"White, Darrell"' showing total 20 results
Start Over Author "White, Darrell" Publisher wiley
20 results on '"White, Darrell"'

1. Outcome of carfilzomib/pomalidomide‐based regimens after daratumumab‐based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis

Author

LeBlanc, Richard, primary, Mian, Hira, additional, Reece, Donna, additional, Su, Jiandong, additional, Masih‐Khan, Esther, additional, Chu, Michael, additional, Jimenez‐Zepeda, Victor, additional, Sebag, Michael, additional, Song, Kevin, additional, Louzada, Martha, additional, Kotb, Rami, additional, Visram, Alissa, additional, White, Darrell, additional, Stakiw, Julie, additional, Reiman, Antony, additional, Aslam, Muhammad, additional, Bergstrom, Debra, additional, Kaedbey, Rayan, additional, Gul, Engin, additional, and Venner, Christopher, additional

Published
2023
Full Text
View/download PDF

2. Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial

Author

Richardson, Paul G., primary, Facon, Thierry, additional, Venner, Christopher P., additional, Bahlis, Nizar J., additional, Offner, Fritz, additional, White, Darrell, additional, Karlin, Lionel, additional, Benboubker, Lotfi, additional, Voog, Eric, additional, Yoon, Sung‐Soo, additional, Suzuki, Kenshi, additional, Shibayama, Hirohiko, additional, Zhang, Xiaoquan, additional, Villarreal, Miguel, additional, Twumasi‐Ankrah, Philip, additional, Labotka, Richard, additional, Rifkin, Robert M., additional, Lonial, Sagar, additional, Kumar, Shaji K., additional, Rajkumar, S. Vincent, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

3. Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment

Author

Baljevic, Muhamed, primary, Gasparetto, Cristina, additional, Schiller, Gary J., additional, Tuchman, Sascha A., additional, Callander, Natalie S., additional, Lentzsch, Suzanne, additional, Monge, Jorge, additional, Kotb, Rami, additional, Bahlis, Nizar J., additional, White, Darrell, additional, Chen, Christine I., additional, Sutherland, Heather J., additional, Madan, Sumit, additional, LeBlanc, Richard, additional, Sebag, Michael, additional, Venner, Christopher P., additional, Bensinger, William I., additional, Biran, Noa, additional, DeCastro, Andrew, additional, Van Domelen, Dane R., additional, Zhang, Chris, additional, Shah, Jatin J., additional, Shacham, Sharon, additional, Kauffman, Michael G., additional, Bentur, Ohad S., additional, and Lipe, Brea, additional

Published
2022
Full Text
View/download PDF

4. Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database

Author

Mian, Hira, primary, LeBlanc, Richard, additional, Louzada, Martha, additional, Masih‐Khan, Esther, additional, McCurdy, Arleigh, additional, Venner, Christopher P., additional, Stakiw, Julie, additional, Kardjadj, Moustafa, additional, Jimenez‐Zepeda, Victor H., additional, Sebag, Michael, additional, White, Darrell, additional, Aslam, Muhammad, additional, Song, Kevin, additional, Reiman, Anthony, additional, Kotb, Rami, additional, Gul, Engin, additional, and Reece, Donna, additional

Published
2022
Full Text
View/download PDF

5. Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database

Author

McCurdy, Arleigh, primary, Louzada, Martha, additional, Venner, Christopher P., additional, Visram, Alissa, additional, Masih‐Khan, Esther, additional, Kardjadj, Moustafa, additional, Jimenez‐Zepeda, Victor H., additional, LeBlanc, Richard, additional, Sebag, Michael, additional, Song, Kevin, additional, White, Darrell, additional, Mian, Hira, additional, Stakiw, Julie, additional, Reiman, Anthony, additional, Aslam, Muhammad, additional, Kotb, Rami, additional, Gul, Engin, additional, and Reece, Donna, additional

Published
2022
Full Text
View/download PDF

6. Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database

Author

LeBlanc, Richard, primary, Mian, Hira, additional, Reece, Donna, additional, Masih‐Khan, Esther, additional, Kardjadj, Moustafa, additional, Jimenez‐Zepeda, Victor H., additional, McCurdy, Arleigh, additional, Song, Kevin, additional, Sebag, Michael, additional, Louzada, Martha, additional, White, Darrell, additional, Stakiw, Julie, additional, Kotb, Rami, additional, Reiman, Anthony, additional, Aslam, Muhammad, additional, Gul, Engin, additional, and Venner, Christopher P., additional

Published
2022
Full Text
View/download PDF

7. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

Author

Richardson, Paul G., primary, Schjesvold, Fredrik, additional, Weisel, Katja, additional, Moreau, Philippe, additional, Anderson, Larry D., additional, White, Darrell, additional, Rodriguez‐Otero, Paula, additional, Sonneveld, Pieter, additional, Engelhardt, Monika, additional, Jenner, Matthew, additional, Corso, Alessandro, additional, Dürig, Jan, additional, Pavic, Michel, additional, Salomo, Morten, additional, Beksac, Meral, additional, Oriol, Albert, additional, Lindsay, Jindriska, additional, Liberati, Anna Marina, additional, Galli, Monica, additional, Robak, Pawel, additional, Larocca, Alessandra, additional, Yagci, Munci, additional, Vural, Filiz, additional, Kanate, Abraham S., additional, Jiang, Ruiyun, additional, Grote, Lara, additional, Peluso, Teresa, additional, and Dimopoulos, Meletios, additional

Published
2021
Full Text
View/download PDF

8. Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada

Author

Reece, Donna E., primary, Masih‐Khan, Esther, additional, Atenafu, Ehetu G., additional, Jimenez‐Zepeda, Victor H., additional, McCurdy, Arleigh, additional, Song, Kevin, additional, LeBlanc, Richard, additional, Sebag, Michael, additional, White, Darrell, additional, Cherniawsky, Hannah, additional, Reiman, Anthony, additional, Stakiw, Julie, additional, Louzada, Martha L., additional, Kotb, Rami, additional, Aslam, Muhammad, additional, Gul, Engin, additional, and Venner, Christopher P., additional

Published
2021
Full Text
View/download PDF

9. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN ‐003/ MYX .1 single arm phase II trial

Author

Venner, Christopher P., primary, LeBlanc, Richard, additional, Sandhu, Irwindeep, additional, White, Darrell, additional, Belch, Andrew R., additional, Reece, Donna E., additional, Chen, Christine, additional, Dolan, Sean, additional, Lalancette, Marc, additional, Louzada, Martha, additional, Kew, Andrea, additional, McCurdy, Arleigh, additional, Monteith, Bethany, additional, Reiman, Tony, additional, McDonald, Gail, additional, Sherry, Max, additional, Gul, Engin, additional, Chen, Bingshu E., additional, and Hay, Annette E., additional

Published
2021
Full Text
View/download PDF

10. The impact of lenalidomide maintenance on second‐line chemotherapy in transplant eligible patients with multiple myeloma

Author

Cherniawsky, Hannah M., primary, Kukreti, Vishal, additional, Reece, Donna, additional, Masih‐Khan, Esther, additional, McCurdy, Arleigh, additional, Jimenez‐Zepeda, Victor H., additional, Sebag, Michael, additional, Song, Kevin, additional, White, Darrell, additional, Stakiw, Julie, additional, LeBlanc, Richard, additional, Reiman, Anthony, additional, Louzada, Martha, additional, Aslam, Muhammad, additional, Kotb, Rami, additional, Gul, Engin, additional, Atenafu, Eshetu, additional, and Venner, Christopher P., additional

Published
2021
Full Text
View/download PDF

11. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma

Author

Gasparetto, Cristina, primary, Lentzsch, Suzanne, additional, Schiller, Gary, additional, Callander, Natalie, additional, Tuchman, Sascha, additional, Chen, Christine, additional, White, Darrell, additional, Kotb, Rami, additional, Sutherland, Heather, additional, Sebag, Michael, additional, Baljevic, Muhamed, additional, Bensinger, William, additional, LeBlanc, Richard, additional, Venner, Chris, additional, Bahlis, Nizar, additional, Rossi, Adriana, additional, Biran, Noa, additional, Sheehan, Heidi, additional, Saint‐Martin, Jean‐Richard, additional, Van Domelen, Dane, additional, Kai, Kazuharu, additional, Shah, Jatin, additional, Shacham, Sharon, additional, Kauffman, Michael, additional, and Lipe, Brea, additional

Published
2020
Full Text
View/download PDF

12. Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients

Author

Belch, Andrew, primary, Bahlis, Nizar, additional, White, Darrell, additional, Cheung, Matthew, additional, Chen, Christine, additional, Shustik, Chaim, additional, Song, Kevin, additional, Tosikyan, Axel, additional, Dispenzieri, Angela, additional, Anderson, Kenneth, additional, Brown, Diane, additional, Robinson, Suzanne, additional, Srinivasan, Shankar, additional, and Facon, Thierry, additional

Published
2020
Full Text
View/download PDF

13. Low‐depth sequencing for copy number abnormalities in multiple myeloma supersedes fluorescent in situ hybridization in scope and resolution

Author

Elnenaei, Manal O., primary, Knopf, Philipp, additional, Cutler, Samuel D., additional, Sinclair, Keaton, additional, Abou El Hassan, Mohamed, additional, Greer, Wenda, additional, Goudie, Marissa, additional, Wagner, Julie, additional, White, Darrell, additional, Couban, Stephen, additional, Forward, Nicholas, additional, Gaston, Daniel, additional, and Campbell, Clinton J.V., additional

Published
2019
Full Text
View/download PDF

14. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth

Author

Dimopoulos, Meletios A., primary, Lonial, Sagar, additional, White, Darrell, additional, Moreau, Philippe, additional, Palumbo, Antonio, additional, San-Miguel, Jesus, additional, Shpilberg, Ofer, additional, Anderson, Kenneth, additional, Grosicki, Sebastian, additional, Spicka, Ivan, additional, Walter-Croneck, Adam, additional, Magen, Hila, additional, Mateos, Maria-Victoria, additional, Belch, Andrew, additional, Reece, Donna, additional, Beksac, Meral, additional, Bleickardt, Eric, additional, Poulart, Valerie, additional, Sheng, Jennifer, additional, Sy, Oumar, additional, Katz, Jessica, additional, Singhal, Anil, additional, and Richardson, Paul, additional

Published
2017
Full Text
View/download PDF

19. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.

Author

Toumishey E, Prasad A, Dueck G, Chua N, Finch D, Johnston J, van der Jagt R, Stewart D, White D, Belch A, and Reiman T

Subjects
Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors adverse effects, Antineoplastic Agents adverse effects, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Immunologic Factors adverse effects, Immunomodulation drug effects, Lenalidomide, Male, Middle Aged, Neoplasm Recurrence, Local drug therapy, Remission Induction, Thalidomide adverse effects, Thalidomide therapeutic use, Angiogenesis Inhibitors therapeutic use, Antineoplastic Agents therapeutic use, Immunologic Factors therapeutic use, Lymphoma, T-Cell, Peripheral drug therapy, Thalidomide analogs & derivatives
Abstract

Background: Patients with T-cell lymphomas face a poorer prognosis compared with patients with B-cell lymphomas. New therapeutic approaches need to be developed to improve outcomes for these patients., Methods: Forty patients with recurrent and refractory T-cell lymphomas other than mycosis fungoides and patients with untreated T-cell lymphoma who were not candidates for combination chemotherapy were prescribed oral lenalidomide at a dose of 25 mg daily on days 1 to 21 of each 28-day cycle, with standardized dose reductions for toxicity. The primary endpoint was overall response rate (ORR), and secondary endpoints were complete and partial response rates, progression-free survival (PFS), overall survival (OS), and safety. The authors also determined duration of response (DoR)., Results: A total of 40 patients were enrolled in the current study; 1 patient was subsequently deemed ineligible. The ORR was 10 of 39 patients (26%); 3 patients (8%) achieved complete responses and 7 patients achieved partial responses. Three patients had stable disease for ≥5 cycles. The median OS was 12 months (range <1 month to ≥69 months), the median PFS was 4 months (range, <1 month to ≥50 months), and the median DoR was 13 months (range 2 months to ≥37 months), including 5 responses that lasted >1 year. Toxicity was in keeping with the known safety profile of lenalidomide. Among the patients who had recurrent/refractory peripheral T-cell lymphoma (29 patients), the ORR was 24%, the median OS was 12 months, the median PFS was 4 months, and the median DoR was 5 months (range, 2 months to ≥37 months)., Conclusions: In the current study, the use of oral lenalidomide monotherapy demonstrated clinically relevant efficacy among patients with systemic T-cell lymphomas. It appears to have excellent potential as an agent in combination therapy for patients with T-cell lymphoma., (© 2014 American Cancer Society.)

Published
2015
Full Text
View/download PDF

20. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.

Author

White D, Kassim A, Bhaskar B, Yi J, Wamstad K, and Paton VE

Subjects
Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bevacizumab, Boronic Acids administration & dosage, Bortezomib, Disease-Free Survival, Drug Resistance, Neoplasm, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multiple Myeloma mortality, Multiple Myeloma pathology, Neoplasm Recurrence, Local mortality, Neoplasm Recurrence, Local pathology, Proportional Hazards Models, Pyrazines administration & dosage, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Multiple Myeloma drug therapy, Neoplasm Recurrence, Local drug therapy
Abstract

Background: Newer systemic therapies have significantly advanced the treatment of multiple myeloma, but additional agents are needed. Bortezomib is a proteasome inhibitor with efficacy in relapsed/refractory multiple myeloma that inhibits tumor angiogenesis, a process that has been implicated in multiple myeloma pathogenesis., Methods: In AMBER("A Randomized, Blinded, Placebo-Controlled, Multicenter, Phase II Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma"), patients with relapsed or refractory multiple myeloma were randomized to receive bortezomib (1.3 mg/m(2) on days 1, 4, 8, and 11 of each 21-day cycle) and either placebo or bevacizumab (15 mg/kg on day 1 of each cycle) for up to 8 cycles. At completion, patients in the bortezomib-plus-bevacizumab arm could continue bevacizumab until they developed progressive disease or unacceptable toxicity. The primary endpoint was progression-free survival (PFS)., Results: The stratified hazard ratio of PFS for the bevacizumab-containing arm (n = 49) relative to the bortezomib monotherapy arm (n = 53) was 0.743 (95% confidence interval [CI], 0.43-1.28; P = .2804); the median PFS was 6.2 months (95% CI, 4.4-8.5 months) and 5.1 months (95% CI, 4.2-7.2 months), respectively; the overall response rates were 51% and 43.4% (P = .4029), respectively; and the median response duration was 6.9 months (95% CI, 4.73-11.83 months) and 6.0 months (95% CI, 4.86-8.31 months), respectively. Frequent adverse events occurred at similar rates across treatment arms, but hypertension, fatigue, and neuralgia occurred more frequently in the bevacizumab-containing arm., Conclusions: The addition of bevacizumab to bortezomib in unselected patients with pretreated multiple myeloma did not result in significant improvements in efficacy outcomes. The combination was well tolerated, and no new safety concerns for either agent were identified., (Copyright © 2012 American Cancer Society.)

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results